论文部分内容阅读
目的:探讨CITP患者外周血CTLA-4表达比例的变化与发病机制的关系,分析紫癜圣愈散治疗CITP可能的作用机制。方法:采用流式细胞术检测CITP患者治疗前后外周血CD4+CD2+5T细胞中CTLA-4的表达比例。结果:治疗组和对照组两组患者在经过治疗后血小板计数分别与治疗前比较,均有统计学意义(P<0.05),组间比较无统计学意义(P>0.05)。两组外周血CD4+CD2+5 T细胞中CTLA-4+细胞的表达比例治疗后与治疗前比较,均有显著差异(P<0.05),治疗前后均明显低于正常组(P<0.01),组间比较无显著差异(P>0.05)。结论:CITP患者CTLA-4表达比例低于正常组,紫癜圣愈散和泼尼松均可上调其表达比例,提示紫癜圣愈散可能是通过调节细胞免疫功能而发挥其治疗作用。
Objective: To investigate the relationship between CTLA-4 expression and pathogenesis in peripheral blood of CITP patients, and to analyze the possible mechanism of CITP by purpura Shengyu powder. Methods: Flow cytometry was used to detect the expression of CTLA-4 in peripheral blood CD4 + CD2 + 5T cells before and after treatment in CITP patients. Results: The platelet counts in the two groups after treatment were significantly different from those before treatment (P <0.05). There was no significant difference between the two groups (P> 0.05). The ratio of CTLA-4 + cells in CD4 + CD25 + T cells in both groups after treatment was significantly lower than that before treatment (P <0.05), and both of them were significantly lower than those before treatment (P <0.01) , There was no significant difference between the two groups (P> 0.05). CONCLUSION: CTLA-4 expression in CITP patients is lower than that in normal controls. Purpura Shengyu Powder and prednisone can up-regulate the expression of CTLA-4, suggesting that purpuric Shengyu Powder may play a therapeutic role by regulating cellular immune function.